Establishment Labs reports Q2 EPS (65c), consensus (72c)

Reports Q2 revenue $48.6M, consensus $47.4M. “The second quarter was another record for Establishment Labs as we continue to grow well in excess of our underlying markets,” said Juan Jose Chacon-Quiros, CEO. “The momentum in our business remains high and with the ongoing global roll-out of Mia Femtech and the pending approval of Motiva in China, we are well positioned to have a strong finish to the year. We now have fourteen Mia clinic partners and the early response to our direct-to-consumer activities is proving that Mia is drawing new women into breast aesthetics as they find significant value in a true minimally invasive offering. Our U.S. PMA is progressing through the approval process and our preparations for commercialization continue in earnest.”